首页> 外文期刊>The Journal of Experomental Medicine >Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers
【24h】

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers

机译:HLA-肽四聚体筛选后,巨细胞病毒特异的CTL过继转移至干细胞移植患者

获取原文
           

摘要

Stem cell transplantation is used widely in the management of a range of diseases of the hemopoietic system. Patients are immunosuppressed profoundly in the early posttransplant period, and reactivation of cytomegalovirus (CMV) remains a significant cause of morbidity and mortality. Adoptive transfer of donor-derived CMV-specific CD8+ T cell clones has been shown to reduce the rate of viral reactivation; however, the complexity of this approach severely limits its clinical application. We have purified CMV-specific CD8+ T cells from the blood of stem cell transplant donors using staining with HLA–peptide tetramers followed by selection with magnetic beads. CMV-specific CD8+ cells were infused directly into nine patients within 4 h of selection. Median cell dosage was 8.6 × 103/kg with a purity of 98% of all T cells. CMV-specific CD8+ T cells became detectable in all patients within 10 d of infusion, and TCR clonotype analysis showed persistence of infused cells in two patients studied. CMV viremia was reduced in every case and eight patients cleared the infection, including one patient who had a prolonged history of CMV infection that was refractory to antiviral therapy. This novel approach to adoptive transfer has considerable potential for antigen-specific T cell therapy.
机译:干细胞移植广泛用于造血系统疾病的治疗。患者在移植后的早期就受到了严重的免疫抑制,巨细胞病毒(CMV)的重新激活仍然是发病率和死亡率的重要原因。已经证明,过继转移供体来源的CMV特异性CD8 + T细胞克隆可降低病毒的再激活率;但是,这种方法的复杂性严重限制了其临床应用。我们已经使用HLA-肽四聚体染色从干细胞移植供体的血液中纯化了CMV特异性CD8 + T细胞,随后用磁珠进行了选择。在选择的4小时内,将CMV特异性CD8 +细胞直接注入9名患者。中位细胞剂量为8.6×103 / kg,纯度为所有T细胞的98%。在输注后10 d内,所有患者均可检测到CMV特异性CD8 + T细胞,TCR克隆型分析显示两名研究患者的输注细胞持续存在。在每种情况下,CMV病毒血症均得到降低,八名患者清除了感染,包括一名抗病毒治疗难以治愈的CMV感染病史较长的患者。这种过继转移的新方法对于抗原特异性T细胞疗法具有相当大的潜力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号